PATENT CLAIMS:

1. An agent characterized in that it is or comprises at least one component of at least one of groups (A) to (R) comprised of:

A) Val and Asp, Met and Ile, Asp and Val, Gln and Pro, Thr and Pro, Leu and Asp, Asp and Ser, Arg and His, Thr and Tyr, Val and Tyr, Arg and Pro, Pro and Leu, Leu and Pro, Pro and Ser, Ser and Pro, Leu and Lys, Lys and Ala, Ala and Thr, Thr and Thr, Thr and Asn, Asn and Ser, Ser and Lys, Lys and Leu, Leu and Met, Met and Met, Met and Tyr, Trp and His, His and Trp, Trp and Gln, Gln and Trp, Trp and Thr, Thr and Pro, Pro and Trp, Trp and Ser, Ser and Ile, Ile and Gln, Gln and Pro;

B) Leu and Asp and Ser, Val and Asp and Met, Asp and Met and Ile, Met and Ile and Asn, Asp and Val and Gln, Val and Gln and Pro, Gln and Pro and Leu, Gln and Pro and Met, Pro and Leu and Thr, Leu and Thr and Pro, Leu and Asp and Ser, Asp and Ser and Ser, Asp and Ser and Cys, Arg and His and Ala, His and Ala and Thr, Ala and Thr and Tyr, Val and Tyr and Ser, Tyr and Ser and Ser, Arg and Pro and Leu, Pro and Leu and Pro, Leu and Pro and Ser, Pro and Ser and Pro, Leu and Lys and Ala, Lys and Ala and Thr, Ala and Thr and Thr, Thr and Thr and Asn, Thr and Asn and Ser, Asn and Ser and Lys, Ser

and Lys and Leu, Lys and Leu and Met, Leu and Met and Met, Met and Met and Tyr, Trp and His and Trp, His and Trp and Gln, Trp and Gln and Trp, Gln and Trp and Thr, Trp and Thr and Pro, Thr and Pro and Trp, Pro and Trp and Ser, Trp and Ser and Ile, Ser and Ile and Gln, Ile and Gln and Pro;

C) Val and Asp and Met and Ile, Asp and Val and Ile and Pro, Leu and Asp and Ser and Ser, Arg and His and Ala and Tyr, His and Ala and Thr and Tyr, Val and Tyr and Ser and Ser, Arg and Pro and Leu and Pro, Pro and Leu and Pro and Ser, Leu and Pro and Ser and Pro, Leu and Lys and Ala and Thr, Lys and Ala and Thr and Thr, Ala and Thr and Thr and Asn and Thr and Thr and Asn and Ser, Thr and Asn and Ser and Lys, Asn and Ser and Lys and Leu, Ser and Lys and Leu and Met, Lys and Leu and Met and Met, Leu and Met and Met and Tyr, Trp and His and Trp and Gln, His and Trp and Gln and Trp, Trp and Gln and Trp and Thr, Gln and Trp and Thr and Pro, Trp and

Thr and Pro and Trp and Ser, Pro and Trp and Ser and Ile, Trp and Ser and Ile and Gln, Ser and Ile and Gln and Pro;

D) Val and Asp and Met and Ile and Asn, Asp and Met and Ile and Asn and Asp, Met and Ile and Asn and Asp and Val, Ile and Asn and Asp and Val and Gln, Asn and Asp and Val and Gln and Pro, Asp and Val and Gln and Pro and Leu, Val and Gln and Pro and Leu

and Thr, Gln and Pro and Leu and Thr and Pro, Leu and Asp and Ser and Ser and Arg, Arg and His and Ala and Thr and Tyr, Leu and Lys and Ala and Thr and Thr, Lys and Ala and Thr and Thr and Asn, Ala and Thr and Thr and Asn and Ser, Thr and Thr and Asn and Ser and Lys, Thr and Asn and Ser and Lys and Leu, Asn and Ser and Lys and Leu and Met, Ser and Lys and Leu and Met and Met, Lys and Leu and Met and Met and Tyr, Trp and His and Trp and Gln and Trp, His and Trp and Gln and Trp and Thr, Trp and Gln and Trp and Thr and Pro, Gln and Trp and Thr and Pro and Trp, Trp and Thr and Pro and Trp and Ser, Trp and Thr and Pro and Trp and Ile, Thr and Pro and Trp and Ile and Gln, Pro and Trp and Ile and Gln and Pro;

E) Val and Asp and Met and Ile and Asn and Asp, Val and Gln and Pro and Leu and Thr and Pro, His and Ser and Pro and Leu and Asp and Ser, Ser and Arg and His and Ala and Thr and Tyr, Leu and Lys and Ala and Thr and Thr and Asn, Lys and Ala and Thr and Thr and Asn and Ser, Ala and Thr and Thr and Asn and Ser and Lys, Thr and Thr and Asn and Ser and Lys and Leu, Thr and Asn and Ser and Lys and Leu and Met, Asn and Ser and Lys and Leu and Met and Met, Ser and Lys and Leu and Met and Met and Tyr, Trp and His and Trp and Gln and Trp and Thr, Trp and Gln and Trp and Thr and Pro and Trp, Trp and Thr and Thr and Pro and Trp and Ser and Ile, Pro and Trp and Ser and Ile and Gln and Pro;

F) Asp and Val and Gln and Pro and Leu and Thr and Pro, Leu and Asp and Ser and Ser and Arg and His and Ala, Ser and Ser and Arg and His and Ala and Thr and Tyr, Leu and Lys and Ala and Thr and Thr and Asn and Ser, Lys and Ala and Thr and Thr and Asn and Ser and Lys, Ala and Thr and Thr and Asn and Ser and Lys and Leu, Thr and Thr and Asn and Ser and Lys and Leu and Met, Thr and Asn and Ser and Lys and Leu and Met and Met, Asn and Ser and Lys and Leu and Met and Met and Tyr, Trp and His and Trp and Gln and Trp and Thr and Pro, Gln and Trp and Thr and Pro and Trp and Ser and Ile, Thr and Pro and Trp and Ser and Ile and Gln and Pro;

G) At least two components of at least one of the groups A) to F);

H) Sequences 1 through 27 of the sequence protocol which comprise all 12 amino acids with the positions 1 through 12 or contain them;

I) Amino acid sequences which in the positions 1, 2, 3 and 4 contain the amino acids LEU, LYS, ALA and THR;

J) Amino acid sequences which in the positions 6, 7, 8 and 9 contain the amino acids Asn, Ser, Lys and Leu;

K) Amino acid sequences which are a combination of the features I) and J);

L) amino acid sequences which contain Gln, Trp and Thr in

the positions 4, 5 and 6;

M) amino acid sequences which contain the amino acid Arg and His in the positions 8 and 9;

N) Amino acid sequences which contain the acids Thr and Tyr in the positions 11 and 12;

0) All subcombinations with two or three elements from the groups L), M) and N);

P) Amino acid sequences which contain amino acids Val and Tyl in the positions 1 and 2;

Q) Amino acid sequences which contain the acids Arg, Pro, Leu, Pro, Ser and Pro in the positions 7, 8, 9, 10, 11, 12; and

R) Amino acid sequences which are a combination of N) and O).

2. The agent according to claim 1 characterized in that it is present in solid, semiliquid or liquid form.

3. The agent according to claim 1 or 2 characterized in that it is present in the form of an injection solution, drop, juice, syrup, spray, suspension, granulate, tablet, pellet, transdermal therapeutic system, capsule, plaster, suppository, salve, cream, lotion, gel, emulsion or aerosol form.

4. The agent according to claim 3 characterized in that it contains an auxiliary substance like, for example, a carrier, a filler, a solvent, a diluent, a surface active substance, a coloring agent, a preservative, a bursting agent, a smoothing agent, a lubricant, an aromatizing agent and/or a binder.

5. The agent according to one of claims 1 to 4 characterized in that it is modified or substituted by at least one component from the group of sugar residues, glucor acid, sulfate residues, serine, glycine or aspartate.

6. A nucleic acid coding for a peptide according to claim 1.

7. A nucleic acid according to claim 6 characterized in that it is a DNA, an RNA, an mRNA or a mixture of at least two of these components.

8. A nucleic acid of one of claims 5 to 7 characterized in that it is present as the naked nucleic acid or as a packed nucleic acid bonded as a vector or plasmid or in a liposome or

present as a phage.

9. The method of making an agent according to claim 1 characterized in that a solid phase synthesis or a synthesis in liquid phase is used.

10. The method of making an agent according to claim 1 characterized in that a peptide according to claim 1 is expressed by a nucleic acid coding for this peptide sequence.

11. The use of the peptide according to claim 1 to produce a pharmaceutical.

12. A method of healing or treating or a method for preventing the illness TSE characterized in that in the patient there is an enrichment with an agent according to one of claims 1 to 5 and/or a nucleic acid according to claims 6 to 8.